Verrica Historical Balance Sheet

VRCA Stock

USD 0.68 0.01 1.45%

Trend analysis of Verrica Pharmaceuticals balance sheet accounts such as Total Assets of 62 M, Other Current Liab of 16.7 M, Total Current Liabilities of 15.5 M or Total Stockholder Equity of 39.3 M provides information on Verrica Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Verrica Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Verrica Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Verrica Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Verrica Pharmaceuticals is a good buy for the upcoming year.

Verrica Pharmaceuticals Inventory

1.23 Million

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verrica Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.

About Verrica Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Verrica Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Verrica Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Verrica Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Verrica currently owns. An asset can also be divided into two categories, current and non-current.

Verrica Pharmaceuticals Balance Sheet Chart

At present, Verrica Pharmaceuticals' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 39.3 M, whereas Total Assets are forecasted to decline to about 62 M.

Total Assets Other Current Liab Total Current Liabilities Accounts Payable

Add Fundamental

Total Assets

Total assets refers to the total amount of Verrica Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Verrica Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Verrica Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Verrica Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Verrica Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Verrica Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Verrica Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Verrica Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verrica Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.At present, Verrica Pharmaceuticals' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 39.3 M, whereas Total Assets are forecasted to decline to about 62 M.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	2.4M	13.9M	15.9M	16.7M
Total Assets	44.7M	81.6M	93.8M	62.0M

Other Current Liab Total Assets

Verrica Pharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Short Long Term Debt	Preferred Stock Total Equity	Total Current Assets	Short Term Debt	Common Stock	Common Stock Total Equity	Net Invested Capital	Net Working Capital	Property Plant And Equipment Net	Other Assets
Total Assets		0.63	0.66	0.8	0.9	-0.39	-0.78	0.73	0.76	1.0	0.59	0.56	0.91	0.63	0.78	0.69	0.94	0.87	1.0	0.4	0.9	0.84	0.99	0.89	0.72	-0.04
Other Current Liab	0.63		0.4	0.24	0.43	-0.28	-0.87	0.97	0.79	0.6	0.81	0.93	0.67	0.32	0.88	0.92	0.72	0.47	0.63	-0.03	0.71	0.77	0.57	0.6	0.56	-0.53
Total Current Liabilities	0.66	0.4		0.27	0.33	0.35	-0.6	0.36	0.23	0.64	0.41	0.48	0.62	0.66	0.59	0.71	0.63	0.55	0.64	0.9	0.53	0.47	0.65	0.26	0.79	0.11
Total Stockholder Equity	0.8	0.24	0.27		0.96	-0.61	-0.4	0.42	0.63	0.83	0.11	0.13	0.64	0.51	0.44	0.21	0.74	0.73	0.8	0.18	0.67	0.55	0.85	0.85	0.41	0.17
Net Tangible Assets	0.9	0.43	0.33	0.96		-0.63	-0.56	0.59	0.75	0.91	0.35	0.31	0.78	0.52	0.59	0.38	0.84	0.76	0.91	0.15	0.78	0.72	0.92	0.95	0.5	0.04
Net Debt	-0.39	-0.28	0.35	-0.61	-0.63		0.2	-0.4	-0.76	-0.42	-0.12	-0.12	-0.31	0.01	-0.19	-0.01	-0.35	-0.32	-0.41	0.52	-0.4	-0.4	-0.4	-0.71	0.09	0.36
Retained Earnings	-0.78	-0.87	-0.6	-0.4	-0.56	0.2		-0.85	-0.72	-0.73	-0.87	-0.78	-0.91	-0.71	-0.98	-0.87	-0.9	-0.7	-0.76	-0.25	-0.9	-0.92	-0.71	-0.63	-0.86	0.41
Accounts Payable	0.73	0.97	0.36	0.42	0.59	-0.4	-0.85		0.85	0.71	0.77	0.84	0.73	0.34	0.88	0.87	0.79	0.56	0.74	-0.05	0.77	0.8	0.69	0.74	0.55	-0.48
Cash	0.76	0.79	0.23	0.63	0.75	-0.76	-0.72	0.85		0.77	0.57	0.66	0.7	0.32	0.71	0.66	0.77	0.6	0.78	-0.12	0.76	0.77	0.75	0.86	0.42	-0.5
Cash And Short Term Investments	1.0	0.6	0.64	0.83	0.91	-0.42	-0.73	0.71	0.77		0.53	0.53	0.88	0.59	0.74	0.65	0.92	0.86	1.0	0.4	0.87	0.81	0.99	0.9	0.67	-0.02
Common Stock Shares Outstanding	0.59	0.81	0.41	0.11	0.35	-0.12	-0.87	0.77	0.57	0.53		0.74	0.79	0.46	0.84	0.76	0.67	0.56	0.59	0.03	0.79	0.88	0.47	0.5	0.67	-0.45
Non Current Liabilities Total	0.56	0.93	0.48	0.13	0.31	-0.12	-0.78	0.84	0.66	0.53	0.74		0.58	0.22	0.79	0.91	0.63	0.39	0.55	0.1	0.61	0.67	0.51	0.46	0.54	-0.29
Capital Surpluse	0.91	0.67	0.62	0.64	0.78	-0.31	-0.91	0.73	0.7	0.88	0.79	0.58		0.79	0.89	0.7	0.95	0.85	0.9	0.33	0.98	0.97	0.86	0.78	0.87	-0.2
Other Current Assets	0.63	0.32	0.66	0.51	0.52	0.01	-0.71	0.34	0.32	0.59	0.46	0.22	0.79		0.71	0.45	0.78	0.67	0.61	0.57	0.73	0.68	0.63	0.38	0.93	-0.06
Other Stockholder Equity	0.78	0.88	0.59	0.44	0.59	-0.19	-0.98	0.88	0.71	0.74	0.84	0.79	0.89	0.71		0.88	0.92	0.7	0.77	0.23	0.9	0.91	0.73	0.64	0.86	-0.35
Total Liab	0.69	0.92	0.71	0.21	0.38	-0.01	-0.87	0.87	0.66	0.65	0.76	0.91	0.7	0.45	0.88		0.75	0.5	0.68	0.35	0.69	0.72	0.64	0.49	0.71	-0.38
Short Long Term Debt	0.94	0.72	0.63	0.74	0.84	-0.35	-0.9	0.79	0.77	0.92	0.67	0.63	0.95	0.78	0.92	0.75		0.82	0.93	0.35	0.94	0.91	0.93	0.82	0.85	-0.16
Preferred Stock Total Equity	0.87	0.47	0.55	0.73	0.76	-0.32	-0.7	0.56	0.6	0.86	0.56	0.39	0.85	0.67	0.7	0.5	0.82		0.86	0.36	0.91	0.79	0.82	0.74	0.7	0.02
Total Current Assets	1.0	0.63	0.64	0.8	0.91	-0.41	-0.76	0.74	0.78	1.0	0.59	0.55	0.9	0.61	0.77	0.68	0.93	0.86		0.38	0.9	0.84	0.99	0.91	0.69	-0.06
Short Term Debt	0.4	-0.03	0.9	0.18	0.15	0.52	-0.25	-0.05	-0.12	0.4	0.03	0.1	0.33	0.57	0.23	0.35	0.35	0.36	0.38		0.23	0.13	0.43	-0.02	0.6	0.36
Common Stock	0.9	0.71	0.53	0.67	0.78	-0.4	-0.9	0.77	0.76	0.87	0.79	0.61	0.98	0.73	0.9	0.69	0.94	0.91	0.9	0.23		0.97	0.85	0.81	0.81	-0.21
Common Stock Total Equity	0.84	0.77	0.47	0.55	0.72	-0.4	-0.92	0.8	0.77	0.81	0.88	0.67	0.97	0.68	0.91	0.72	0.91	0.79	0.84	0.13	0.97		0.78	0.78	0.79	-0.31
Net Invested Capital	0.99	0.57	0.65	0.85	0.92	-0.4	-0.71	0.69	0.75	0.99	0.47	0.51	0.86	0.63	0.73	0.64	0.93	0.82	0.99	0.43	0.85	0.78		0.89	0.69	0.01
Net Working Capital	0.89	0.6	0.26	0.85	0.95	-0.71	-0.63	0.74	0.86	0.9	0.5	0.46	0.78	0.38	0.64	0.49	0.82	0.74	0.91	-0.02	0.81	0.78	0.89		0.43	-0.14
Property Plant And Equipment Net	0.72	0.56	0.79	0.41	0.5	0.09	-0.86	0.55	0.42	0.67	0.67	0.54	0.87	0.93	0.86	0.71	0.85	0.7	0.69	0.6	0.81	0.79	0.69	0.43		-0.09
Other Assets	-0.04	-0.53	0.11	0.17	0.04	0.36	0.41	-0.48	-0.5	-0.02	-0.45	-0.29	-0.2	-0.06	-0.35	-0.38	-0.16	0.02	-0.06	0.36	-0.21	-0.31	0.01	-0.14	-0.09

Click cells to compare fundamentals

Verrica Pharmaceuticals Account Relationship Matchups

Verrica Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	74.2M	80.1M	44.7M	81.6M	93.8M	62.0M
Other Current Liab	2.9M	3.3M	2.4M	13.9M	15.9M	16.7M
Total Current Liabilities	39.5M	46.1M	3.5M	17.0M	19.6M	15.5M
Total Stockholder Equity	33.0M	32.6M	40.0M	19.8M	22.7M	39.3M
Net Tangible Assets	65.0M	33.0M	32.6M	40.0M	46.0M	39.3M
Net Debt	24.6M	27.7M	(32.7M)	(24.0M)	(27.6M)	(29.0M)
Retained Earnings	(103.9M)	(139.0M)	(163.5M)	(230.4M)	(207.4M)	(197.0M)
Accounts Payable	348K	845K	507K	2.5M	2.8M	3.0M
Cash	10.7M	15.8M	34.3M	69.5M	80.0M	84.0M
Non Current Assets Total	8.7M	5.8M	5.6M	4.1M	4.7M	4.1M
Non Currrent Assets Other	3.7M	295K	276K	452K	519.8K	1.0M
Cash And Short Term Investments	65.5M	70.4M	34.3M	69.5M	80.0M	55.1M
Common Stock Shares Outstanding	25.0M	27.0M	34.2M	45.3M	52.1M	29.0M
Liabilities And Stockholders Equity	74.2M	80.1M	44.7M	81.6M	93.8M	62.0M
Non Current Liabilities Total	35.3M	1.5M	1.2M	44.8M	51.5M	54.1M
Capital Surpluse	126.6M	136.9M	171.6M	203.5M	234.0M	120.4M
Other Current Assets	4.4M	7.9M	8.7M	2.5M	2.9M	3.9M
Other Stockholder Equity	136.9M	171.6M	203.5M	250.2M	287.7M	302.1M
Total Liab	41.2M	47.5M	4.7M	61.8M	71.1M	74.7M
Total Current Assets	65.5M	74.3M	39.1M	77.5M	89.2M	57.9M
Short Term Debt	35.7M	41.9M	594K	700K	805K	764.8K
Net Invested Capital	68.3M	74.3M	40.0M	62.6M	72.0M	64.1M
Net Working Capital	28.2M	28.3M	35.7M	60.5M	69.6M	48.9M
Property Plant And Equipment Net	4.9M	5.8M	5.6M	3.6M	4.2M	4.1M
Other Assets	1.6M	295K	276K	1.0	0.9	0.86
Retained Earnings Total Equity	(61.2M)	(103.9M)	(139.0M)	(163.5M)	(147.1M)	(154.5M)
Property Plant And Equipment Gross	4.9M	5.8M	6.0M	4.8M	5.5M	4.4M
Property Plant Equipment	2.2M	4.9M	3.9M	3.9M	4.5M	3.3M
Short Long Term Debt Total	35.3M	43.4M	1.5M	45.5M	52.3M	27.7M
Capital Lease Obligations	1.9M	1.7M	1.5M	2.6M	3.0M	1.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GM	General Motors
C	Citigroup

When determining whether Verrica Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verrica Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verrica Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verrica Pharmaceuticals Stock:

How To Invest In Verrica

Details

Is Verrica Stock a good investment?

Details

What is Verrica Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.

You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verrica Pharmaceuticals. If investors know Verrica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verrica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.84)

Revenue Per Share

0.198

Quarterly Revenue Growth

27.445

Return On Assets

(0.71)

Return On Equity

(20.60)

The market value of Verrica Pharmaceuticals is measured differently than its book value, which is the value of Verrica that is recorded on the company's balance sheet. Investors also form their own opinion of Verrica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Verrica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verrica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Verrica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Verrica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verrica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verrica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Verrica Historical Balance Sheet

Verrica Pharmaceuticals Inventory

1.23 Million

About Verrica Balance Sheet Analysis

Verrica Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Verrica Pharmaceuticals balance sheet Correlations

Verrica Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Verrica Pharmaceuticals balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Net Invested Capital	+ 0.99	Total Assets
Net Invested Capital	+ 0.99	Cash And Short Term Investments
Net Invested Capital	+ 0.99	Total Current Assets

Other Stockholder Equity	- 0.98	Retained Earnings
Common Stock Total Equity	- 0.92	Retained Earnings
Capital Surpluse	- 0.91	Retained Earnings
Common Stock	- 0.9	Retained Earnings
Short Long Term Debt	- 0.9	Retained Earnings
Total Liab	- 0.87	Retained Earnings